CAR T-cell therapy for pancreatic cancer

Carl J. DeSelm, Zachary E. Tano, Anna M. Varghese, Prasad S. Adusumilli

Research output: Contribution to journalReview article

35 Scopus citations

Abstract

Chimeric antigen receptor (CAR) T-cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results in hematological malignancies prompted investigating this approach in solid tumors such as pancreatic cancer. The complex tumor microenvironment, stromal hindrance in limiting immune response, and expression of checkpoint blockade on T cells pose hurdles. Herein, we summarize the opportunities, challenges, and state of knowledge in targeting pancreatic cancer with CAR T-cell therapy.

Original languageEnglish
Pages (from-to)63-74
Number of pages12
JournalJournal of surgical oncology
Volume116
Issue number1
DOIs
StatePublished - Jul 1 2017
Externally publishedYes

Keywords

  • CAR T cells
  • adoptive cell therapy
  • checkpoint blockade
  • chimeric antigen receptor
  • immunotherapy

Fingerprint Dive into the research topics of 'CAR T-cell therapy for pancreatic cancer'. Together they form a unique fingerprint.

  • Cite this

    DeSelm, C. J., Tano, Z. E., Varghese, A. M., & Adusumilli, P. S. (2017). CAR T-cell therapy for pancreatic cancer. Journal of surgical oncology, 116(1), 63-74. https://doi.org/10.1002/jso.24627